At presentation, AnxA1 was significantly higher in the moderate (30.1 (IQR, 16.0–42.0) ng/mL; p < 0.0001) and severe cases of COVID-19 (28.9 (IQR, 17.3–53.6) ng/mL; p < 0.0001) compared to the healthy controls (14.9 (IQR, 10.4–22.4) ng/mL). This evidence concerns the gene ANXA1 and COVID-19.